Radical surgery may be not an optimal treatment approach for pulmonary MALT lymphoma
- 139 Downloads
Primary pulmonary MALT lymphoma is a rare disease, and no standard treatments have been defined yet. In this study, 38 consecutive patients from single center were reviewed. Among 25 patients with localized disease, radical surgery were performed in 12 patients, and the other 13 patients had chemotherapy combined with (7 patients) or without (6 patients) radiotherapy. No significant difference in overall survival (OS) was found between patients who received surgery or not; however, patients treated with chemotherapy had superior progression-free survival (PFS) than those treated with upfront surgery (P = 0.032). Among the 12 patients who received radical surgery, 7 were given adjuvant chemotherapy and 1 patient had consolidation radiotherapy. No significant differences in PFS and OS exist between those who received adjuvant treatment or not (P > 0.05). For patients who received chemotherapy, PFS and OS were significantly better for those treated with cyclophosphamide-based therapy than fludarabine-based therapy. At a median follow-up time of 61.1 months, 5- and 10-year PFS rate was 70.0 and 43.0 %, respectively, and 5- and 10-year OS rate was both 81.0 %. In conclusion, we confirmed the indolent behavior and favorable outcome of this disease. In order to preserve lung function and reduce the risks associated with surgery, radiotherapy or rituximab in combination with alkylating drug-based chemotherapy should be considered as first-line option for pulmonary MALT lymphoma.
KeywordsRadical surgery Extranodal marginal zone lymphoma MALT lymphoma Pulmonary lymphoma Prognosis
We thank all physicians at Sun Yat-sen University Cancer Center for allowing us to include their patients. We also appreciate the cooperation of all pathologists at Sun Yat-sen University Cancer Center for their support. This work received grant support from the National Natural Science Foundation of China (contract/grant number: 81400159), the Medical Research Foundation of Guangdong Province (grant number: B2014158), the Young Teachers’ Cultivation Project of Sun Yat-sen University (No. 12ykpy54), and the Outstanding Young Talents Project of Sun Yat-sen University Cancer Center (No. 04190101#).
Conflicts of interest
- 1.A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909–3918.Google Scholar
- 15.Oh SY, Kim WS, Kim JS, Kim SJ, Kwon HC, Lee DH, et al. Pulmonary marginal zone B-cell lymphoma of MALT type—what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2010;89:563–8.CrossRefPubMedGoogle Scholar
- 21.Li AW, Xu JF, Zhou CC, Wu CY, Wang YL. Clinical characteristics and diagnosis of pulmonary mucosa-associated lymphoid tissue-derived (MALT) lymphoma: a retrospective analysis of 29 cases. Zhonghua Zhong Liu Za Zhi Chin J Oncol. 2012;34:390–3.Google Scholar
- 23.Wirth A, Gospodarowicz M, Aleman BM, Bressel M, Ng A, Chao M, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol: Off J Eur Soc Med Oncol ESMO. 2013;24:1344–51.CrossRefGoogle Scholar
- 25.Harada K, Murakami N, Kitaguchi M, Sekii S, Takahashi K, Yoshio K, et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes. Int J Radiat Oncol Biol Phys. 2014;88:650–4.CrossRefPubMedGoogle Scholar
- 27.Yoshida C, Tarumi S, Kato A, Nii K, Chang SS, Yokomise H. Mucosa-associated lymphoid tissue (MALT) lymphoma of the lung treated by surgery and rituximab; report of a case. Kyobu Geka Jpn J Thorac Surg. 2013;66:169–72.Google Scholar
- 28.Zucca E, Conconi A, Laszlo D, Lopez-Guillermo A, Bouabdallah R, Coiffier B, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone b-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31:565–72.CrossRefGoogle Scholar
- 30.Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, et al. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol: Off J Eur Soc Med Oncol ESMO. 2011;22:689–95.CrossRefGoogle Scholar